The U.S. asthma market has become increasingly crowded with a large number of approved therapies. Those include several LABA/ICSFDCs (i.e., GlaxoSmithKline’s Advair and Breo, AstraZeneca’s Symbicort, Merck & Co.’s Dulera, and Teva Pharmaceutical’s AirDuo and its authorized generic), numerous ICSs (e.g., GSK’s Flovent, Teva’s Qvar), a number of SABAs (e.g., Teva’s ProAir, GSK’s Ventolin), montelukast (Merck’s Singulair), Boehringer Ingelheim’s Spiriva, and biologics (Roche’s Xolair, GSK’s Nucala, Teva’s Cinqair, and AstraZeneca’s Fasenra), among others. The market is expected to become even more competitive in the next few years, with upcoming approvals of additional biological agents and triple LABA/LAMA/ICS combinations, making brand differentiation and understanding of key patient characteristics ever more critical for marketers.
Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive real-world data (RWD) repository.
Markets covered: United States
Real-World data: U.S. electronic health records and claims data
Key drugs covered: Advair, Symbicort, Dulera, Breo, AirDuo, salmeterol/fluticasone generic, Xolair, Nucala, Spiriva, Incruse, Qvar, Flovent, ProAir, Ventolin, and others
Key analysis provided: